Literature DB >> 29803661

The role of the NLRP3 inflammasome and the activation of IL-1β in the pathogenesis of chronic viral hepatic inflammation.

Adam Molyvdas1, Urania Georgopoulou2, Nikolaos Lazaridis3, Prodromos Hytiroglou4, Alexios Dimitriadis2, Pelagia Foka2, Themistoklis Vassiliadis5, Georgia Loli3, Athanasios Phillipidis3, Pantelis Zebekakis3, Anastasios E Germenis1, Matthaios Speletas6, Georgios Germanidis7.   

Abstract

BACKGROUND AND AIMS: Chronic viral hepatitis is a prevalent disease with major health implications. Its underlying pathophysiological mechanisms are not fully understood. IL-1β and the NLRP3 inflammasome involvement has been suggested in recent years, from in vitro data and data from peripheral blood samples. Therefore, we investigated IL-1β and the NLRP3 inflammasome in liver tissues in an effort to clarify their role in the pathophysiology of chronic viral hepatitis.
METHODS: We studied liver biopsies from patients with a new diagnosis of either chronic hepatitis B (CHB) and chronic hepatitis C (CHC) or patients with chronic hepatitis B in remission (CHB-rem). The biopsies were separated in two parts. The first part was sent to histology to determine the grade of inflammation and fibrosis. From the second part, RNA was extracted and converted to cDNA used in semi-quantitative Real-Time PCR to measure the levels of IL1B, CASP1, NLRP3, ASC and IL1RA. The cell lines used in the in vitro experiments were Huh7.5, LX2 and THP-1 in variety of combinations of monocultures, co-cultures and triple cultures with one of the cell lines infected with the JFH-1 HCV clone. From the cell cultures RNA was extracted and converted to cDNA. For cell lines, we focused in the expression of IL1B and NLRP3.
RESULTS: The expression of IL1B, CASP1 and NLRP3 were found significantly different between our groups (p = 0.001, p = 0.001 and p = 0.038, respectively). CHB patients displayed significantly higher IL1B and CASP1 mRNA levels compared to both CHB-rem and CHC patients. IL1B expression significantly correlates with liver biochemical data in CHB patients (AST: p = 0.006, r = 0.457; ALT p = 0.002, r = 0.497). Finally, mRNA levels of IL1B in CHB patients significantly correlate with the degree of inflammation (p = 0.016) but not the stage of fibrosis (p = 0.362). Interestingly, the relative expression of IL1B in triple culture experiments in vitro was below of 1.5-fold, suggesting no activation of IL1B. Moreover, no activation of NLRP3 was demonstrated in all investigated in vitro conditions.
CONCLUSION: IL-1β might play an important role in the pathogenesis of chronic hepatic inflammation from HBV, but not from HCV.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Caspase-1; Chronic; HBV; HCV; Hepatitis; IL-1β; Inflammation; NLRP3

Mesh:

Substances:

Year:  2018        PMID: 29803661     DOI: 10.1016/j.cyto.2018.04.032

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  15 in total

1.  Taurine Alleviates Schistosoma-Induced Liver Injury by Inhibiting the TXNIP/NLRP3 Inflammasome Signal Pathway and Pyroptosis.

Authors:  Xin Liu; Ya-Rong Zhang; Chen Cai; Xian-Qiang Ni; Qing Zhu; Jin-Ling Ren; Yao Chen; Lin-Shuang Zhang; Chang-Ding Xue; Jie Zhao; Yong-Fen Qi; Yan-Rong Yu
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

Review 2.  Procyanidins and Their Therapeutic Potential against Oral Diseases.

Authors:  Huan Chen; Wanyu Wang; Shiyang Yu; Huimin Wang; Zilu Tian; Song Zhu
Journal:  Molecules       Date:  2022-05-04       Impact factor: 4.927

3.  The P2X7R-NLRP3 and AIM2 Inflammasome Platforms Mark the Complexity/Severity of Viral or Metabolic Liver Damage.

Authors:  Chiara Rossi; Antonio Salvati; Mariarosaria Distaso; Daniela Campani; Francesco Raggi; Edoardo Biancalana; Domenico Tricò; Maurizia Rossana Brunetto; Anna Solini
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

Review 4.  Inflammasome: A Double-Edged Sword in Liver Diseases.

Authors:  Jingyun Luan; Dianwen Ju
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

5.  Inflammasome Genes' Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment.

Authors:  Shady Z K Estfanous; Sahar A Ali; Sameh M Seif; Sameh H A Soror; Dalia H A Abdelaziz
Journal:  Mediators Inflamm       Date:  2019-01-09       Impact factor: 4.711

6.  The different expression of caspase-1 in HBV-related liver disease and acts as a biomarker for acute-on-chronic liver failure.

Authors:  Xiangying Zhang; Peiling Dong; Lin Xu; Yuan Tian; Huayin Sun; Hongbo Shi; Zhongping Duan; Liyan Chen; Feng Ren
Journal:  BMC Gastroenterol       Date:  2019-08-20       Impact factor: 3.067

Review 7.  Pyroptosis in Liver Disease: New Insights into Disease Mechanisms.

Authors:  Jiali Wu; Su Lin; Bo Wan; Bharat Velani; Yueyong Zhu
Journal:  Aging Dis       Date:  2019-10-01       Impact factor: 6.745

8.  Inflammasomes and their roles in the pathogenesis of viral hepatitis and their related complications: An updated systematic review.

Authors:  Maryam Dadmanesh; Mohammad Mehdi Ranjbar; Khodayar Ghorban
Journal:  Immunol Lett       Date:  2019-03-01       Impact factor: 3.685

Review 9.  Cellular Interplay as a Consequence of Inflammatory Signals Leading to Liver Fibrosis Development.

Authors:  Simona-Rebeca Ignat; Sorina Dinescu; Anca Hermenean; Marieta Costache
Journal:  Cells       Date:  2020-02-18       Impact factor: 6.600

10.  Dihydromyricetin ameliorates chronic liver injury by reducing pyroptosis.

Authors:  Quan-Cheng Cheng; Jing Fan; Xin-Wei Deng; Huai-Cun Liu; Hui-Ru Ding; Xuan Fang; Jian-Wei Wang; Chun-Hua Chen; Wei-Guang Zhang
Journal:  World J Gastroenterol       Date:  2020-11-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.